Maintenance Ruxolitinib
Phase II Study of Maintenance Ruxolitinib After Allogeneic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) in Complete Remission
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 64 patients (estimated)
- Sponsors
- Massachusetts General Hospital
- Collaborators
- Washington University School of Medicine, Ohio State University Comprehensive Cancer Center, Medical College of Wisconsin, Vanderbilt University Medical Center
- Tags
- JAK2 Inhibitor, Tyrosine Kinase (TK) Inhibitor, Maintenance, Post-Allogeneic Stem Cell Transplant
- Trial Type
- Treatment
- Last Update
- 2 months ago
- SparkCures ID
- 1671
- NCT Identifier
- NCT03286530
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.